Entera Bio (ENTX) Current Leases (2019 - 2026)
Entera Bio's (ENTX) quarterly Current Leases came in at $185000.0 in Q1 2026, up 9.47% YoY from $169000.0 in Q1 2025, and down 19.57% on a QoQ basis from $230000.0 in Q4 2025.
Entera Bio (ENTX) Current Leases (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Current Leases data on file, last reported at $185000.0 in Q1 2026.
- Quarterly Current Leases rose 9.47% year-over-year to $185000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185000.0 (up 9.47% YoY) and the FY2025 annual result came in at $230000.0, up 35.29% from the prior year.
- Current Leases eased to $185000.0 in Q1 2026, from $230000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $230000.0 in Q4 2025 to a low of $48000.0 in Q1 2023.
- A 5-year average of $151470.6 and a median of $155000.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases plunged 66.2% — and 2024, when it jumped 218.75%.
- Tracing ENTX's Current Leases over 5 years: stood at $91000.0 in 2022, then jumped by 47.25% to $134000.0 in 2023, then climbed by 26.87% to $170000.0 in 2024, then soared by 35.29% to $230000.0 in 2025, then decreased by 19.57% to $185000.0 in 2026.
- The last three Current Leases figures came in at $185000.0 (Q1 2026), $230000.0 (Q4 2025), and $170000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 199,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 199,000.00 |
| Mar 31, 2026 | 185,000.00 |
| Dec 31, 2025 | 230,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 169,000.00 |
| Dec 31, 2024 | 170,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | 131,000.00 |
| Jun 30, 2023 | 140,000.00 |
| Mar 31, 2023 | 48,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2022 | 129,000.00 |
| Jun 30, 2022 | 172,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Dec 31, 2021 | 179,000.00 |
| Jun 30, 2021 | 184,000.00 |